Le Lézard
Classified in: Health
Subject: SVY

Medical Gas and Equipment Market Worth $20.0 Billion by 2023 - Exclusive Report by MarketsandMarketstm


CHICAGO, December 12, 2018 /PRNewswire/ --

According to the new market research report "Medical Gas and Equipment Market by Type (Oxygen, Nitrous Oxide, Carbon Dioxide, Gas Mixture, Vacuum System, Manifold, VIPR, Hose) Application (Respiratory, Anesthesia, Medical Imaging, Cryosurgery) End User (Hospital, Home Healthcare) - Forecast to 2023", published by MarketsandMarketstm, the market is expected to reach USD 20.0 billion by 2023 from an estimated USD 14.0 billion in 2018, at a CAGR of 6.2%.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Don't miss out on business opportunities in Medical Gas and Equipment Market.

Speak to Our Analyst and gain crucial industry insights that will help your business grow:

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=217979261  

The major factors driving the growth of this market include rising ageing population and sub sequent increase in chronic diseases like COPD and asthma, growing home healthcare market, and growing smoking prevalence.

By product, the Medical Gas Market segment is expected to account for the largest share of the Medical Gas and Equipment Market 

Based on product, the market is broadly divided into medical gases and medical gas equipment. Increasing use of medical gases for the diagnosis and treatment of various respiratory diseases such as COPD, asthma, and other medical conditions such as cardiovascular and lifestyle diseases are further expected to drive the demand of medical gases during the forecast period.

Browse in-depth TOC on "Medical Gas and Equipment Market"

387 - Tables  

53 - Figures  

401 - Pages  

View more detailed TOC:  

https://www.marketsandmarkets.com/Market-Reports/medical-gases-equipment-market-217979261.html

Therapeutic segment will witness the highest growth in the market, by application 

Based on application, the Medical Gas and Equipment Market is segmented into therapeutics, diagnostics, pharmaceutical manufacturing and research, and others. The therapeutic segment is expected to account for the largest share of the global Medical Gas and Equipment Market during the forecast period of 2018 to 2023. The large share of this segment can be attributed to rising incidences of cardiovascular diseases and increasing prevalence of respiratory disorders due to lifestyle changes, rising pollution levels, and growing smoking prevalance.

North America, the largest regional market for medical gases and equipment 

North America is expected to account for the largest share of the Medical Gas and Equipment Market in 2018, followed by Europe and the Asia Pacific. The increasing adoption of technologically advanced medical gases and equipment products, growing ageing population, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, and the presence of a large number of leading medical gases and equipment manufacturers in the region, are responsible for the large share of the North American Medical Gas and Equipment Market.

Request for Free Sample Report:  

https://www.marketsandmarkets.com/requestsampleNew.asp?id=217979261

The prominent players in the Medical Gas and Equipment Market include Air Products and Chemicals, Inc. (U.S.), The Linde Group (Germany), Taiyo Nippon Sanso Corp. (Japan), SOL-SpA (Italy), Air Liquide (France), Praxair, Inc. (U.S.), Atlas Copco (Sweden), Messer Group (Germany), and GCE Holding AB (Sweden).

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

About MarketsandMarketstm  

MarketsandMarketstm provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketstm for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarketstm are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketstm now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketstm is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/medical-gases-equipment-market.asp

Visit Our Website: https://www.marketsandmarkets.com

SOURCE MarketsandMarkets


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: